A5026351398- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Bone and Joint Diseases
- Bone health and treatments
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Acute Lymphoblastic Leukemia research
- Venous Thromboembolism Diagnosis and Management
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- T-cell and Retrovirus Studies
- Cancer Treatment and Pharmacology
- Cutaneous lymphoproliferative disorders research
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- Polyomavirus and related diseases
- Infectious Diseases and Mycology
- Mycobacterium research and diagnosis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cerebrovascular and Carotid Artery Diseases
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
2015-2024
Fondazione Gimema Onlus
2019-2020
Fred Hutch Cancer Center
2017-2019
Azienda Sanitaria Locale Alessandria
2016-2018
University of Modena and Reggio Emilia
2017
Presidio Ospedaliero
2016
High levels of circulating tumor plasma cells (CTC-high) in patients with multiple myeloma are a marker aggressive disease. We aimed to confirm the prognostic impact and identify possible cutoff value CTC-high for prediction progression-free survival (PFS) overall (OS), context concomitant risk features minimal residual disease (MRD) achievement.CTC were analyzed at diagnosis two-tube single-platform flow cytometry (sensitivity 4 × 10-5) enrolled multicenter randomized FORTE clinical trial...
We conducted a phase II study to assess activity and safety profile of bendamustine rituximab in elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) who were prospectively defined as frail using simplified version the Comprehensive Geriatric Assessment (CGA). Patients had be over 70 years age, histologically confirmed DLBCL. Frail those younger than 80 at CGA or older an unfit profile. Treatment consisted 4-6 courses [90 mg/m2 days (d)1-2] (375 d1) administered every 28...
Additional copies of chromosome 1 long arm (1q) are frequently found in multiple myeloma (MM) and predict high-risk disease. Available data suggest a different outcome biology patients with amplification (Amp1q, ≥4 1q) vs. gain (Gain1q, 3 1q. We evaluated the impact Amp1q/Gain1q on newly diagnosed MM enrolled FORTE trial (NCT02203643). Among 400 available 1q data, 52 (13%) had Amp1q 129 (32%) Gain1q. After median follow-up 62 months, progression-free survival (PFS) was 21.2 months group,...
There is no consensus regarding optimal treatment for peripheral T-cell lymphomas (PTCL), especially in relapsed or refractory cases, which have very poor prognosis and a dismal outcome, with 5-year overall survival of 30 %. A multicenter prospective phase II trial was conducted to investigate the role combination gemcitabine plus romidepsin (GEMRO regimen) relapsed/refractory PTCL, looking potential synergistic effect two drugs. GEMRO regimen contemplates an induction six 28-day cycles...
Summary Current data suggests that the risk of venous thromboembolism (VTE) in patients with non-Hodgkin lymphoma (NHL) is comparable to observed solid tumours, although more robust confirmatory analyses are required. With mind, we investigated occurrence VTE a pooled analysis 12 “Fondazione Italiana Linfomi” (FIL) prospective clinical studies. Specifically, wished assess cumulative incidence NHL patients, evaluate predictive value Khorana Score (KS), and identify other potential factors for...
Summary This multicentre phase II study Fondazione Italiana Linfomi (FIL)‐bortezomib plus rituximab bendamustine (BRB) tested a combination of (90 mg/m 2 on days 1–2), (375 intravenously day 1) and bortezomib (1.3 sc 1, 8, 15, 22) every 28 for six cycles in 38 symptomatic patients with relapsed/refractory Waldenstrom macroglobulinaemia (RR‐WM). Moreover, MYD88 L265P CXCR4 S338X mutations were by droplet digital polymerase chain reaction (ddPCR) both at baseline the end treatment 21 patients....
Ocular involvement of chronic graft-versus-host disease (cGVHD) is a complication that occurs in up to 60% patients after allogeneic hematopoietic stem cell transplantation. Conventional therapeutic options include medical and surgical procedures are administered depending on the severity condition, but most them have provided unsatisfactory results and, date, there no consensus about treatment. We considered topical application platelet lysate, as eye drops, might be an alternative...
A non-myeloablative regimen of fludarabine and 200 cGy total body irradiation combined with post-grafting immunosuppression mycophenolate mofetil a calcineurin inhibitor facilitates allogeneic hematopoietic cell transplantation from HLA-matched related or unrelated donors in older patients and/or those comorbidities. However, outcomes prior studies have been disappointing myelodysplastic syndromes myeloproliferative neoplasms due to high incidences progression graft failure (together termed...
Patients with acute myeloid leukemia (AML) during induction chemotherapy and those who receive allogeneic hematopoietic stem cell transplantation (HSCT) are at higher risk of invasive fungal infections (IFI). In the present study, we investigated whether IFI in AML patients receiving HSCT might be affected by antifungal prophylaxis posaconazole administered induction/salvage treatment. Between August 2001 April 2015, 130 received itraconazole/fluconazole (group A) 99 B) as after 7 Italian...
Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin subtype, and approximately 50% of patients are >60 years age. Patients with relapsed/refractory (rr) disease have a poor prognosis currently available treatments. Lenalidomide in Italy for rrDLBCL based on local disposition Italian Drug Agency. Subjects, Materials, Methods An observational retrospective study was conducted 24 hematology centers aim to improve information effectiveness safety...
The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the clinical history patients with chronic lymphocytic leukemia (CLL) in both naïve and relapsed/refractory settings. "Accelerated" (a-CLL) is a relatively rare form CLL representing less than 1 % all cases. a-CLL usually have more aggressive course reduced overall survival was reported conventional chemo-immunotherapy approaches.The role Bruton Tyrosine Kinase-inhibitor, ibrutinib, well established encouraging preliminary...
Clinical trial results indicate that romidepsin, a histone deacetylase inhibitor, is promising treatment in relapsed/refractory T-cell lymphomas (TCLs). This retrospective multicenter study was conducted patients with TCL treated romidepsin monotherapy through Named Patient Program (NPP) Italy. Principal endpoints were overall response rate (ORR), safety, and survival (OS). The ORR 33 evaluable 24.2% an the cutaneous of 35.7%. Global OS 39.3% at 30 months. There not any specific differences...
Bisphosphonates (BPs) are administered to Multiple Myeloma (MM) patients with bone lytic lesion. Osteonecrosis of the Jaw (ONJ) is a complication reported since 2003 in treated intravenous (IV) BPs such as zoledronic acid and pamidronate, 6%-26.3% frequency early literature series, before some preventive measures were recommended. We evaluated occurrence ONJ without dental MM our centre between 1996 2015. Since 2005, (already under treatment or treatment) underwent baseline mouth assessment...
Background: High and comparable rates of response minimal residual disease (MRD) negativity were reported with four 28‐day induction cycles KRd followed by autologous stem‐cell transplantation (ASCT) 4 consolidation (KRd_ASCT_KRd), 12 (KRd12) in newly diagnosed myeloma (NDMM) patients. Of note, both regimens superior to carfilzomib‐cyclophosphamide‐dexamethasone (KCd) ASCT KCd (KCd‐ASCT‐KCd) (Gay F ASH 2018). Aims: We evaluated the benefit KRd_ASCT_KRd vs KRd12 specific subgroups patients...
Hepatosplenic T cell lymphoma (HSTCL) is a type of hematologic neoplasia with poor prognosis and high frequency refractoriness to conventional chemotherapy. The results obtained by dose chemotherapy followed autologous stem cells transplantation seem be more effective option but still unsatisfactory. Also the role allogeneic unclear, although few cases reported on literature would show good in overall survival rates. In this paper, we patient׳s medical history affected αβ variant...